NASDAQ:MDWD MediWound (MDWD) Stock Price, News & Analysis $16.60 -0.60 (-3.49%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$16.32▼$17.4850-Day Range$14.51▼$21.1652-Week Range$7.10▼$24.00Volume55,524 shsAverage Volume105,434 shsMarket Capitalization$154.11 millionP/E RatioN/ADividend YieldN/APrice Target$29.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get MediWound alerts: Email Address MediWound MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside74.7% Upside$29.00 Price TargetShort InterestBearish10.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.03) to ($2.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.06 out of 5 starsMedical Sector751st out of 910 stocksMedicinals & Botanicals Industry9th out of 12 stocks 3.5 Analyst's Opinion Consensus RatingMediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMediWound has only been the subject of 2 research reports in the past 90 days.Read more about MediWound's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.27% of the float of MediWound has been sold short.Short Interest Ratio / Days to CoverMediWound has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MediWound has recently increased by 9.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMediWound does not currently pay a dividend.Dividend GrowthMediWound does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDWD. Previous Next 1.8 News and Social Media Coverage News SentimentMediWound has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MediWound this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for MDWD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediWound insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of MediWound is held by insiders.Percentage Held by Institutions46.83% of the stock of MediWound is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MediWound's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MediWound are expected to decrease in the coming year, from ($2.03) to ($2.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediWound is -12.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediWound is -12.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediWound has a P/B Ratio of 8.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MediWound's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About MediWound Stock (NASDAQ:MDWD)MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Read More MDWD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDWD Stock News HeadlinesSeptember 3, 2024 | markets.businessinsider.comMediWound to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 29, 2024 | americanbankingnews.comHead to Head Review: MediWound (NASDAQ:MDWD) & Jinhua Marine Biological (OTCMKTS:JNMB)September 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 22, 2024 | markets.businessinsider.comMediwound Poised for Growth: Buy Rating Backed by NexoBrid Expansion and EscharEx Market PotentialAugust 21, 2024 | finance.yahoo.comMediWound Ltd.'s (NASDAQ:MDWD) top owners are retail investors with 38% stake, while 28% is held by institutionsAugust 15, 2024 | globenewswire.comMediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal BurnsAugust 15, 2024 | markets.businessinsider.comBuy Rating Justified by MediWound’s Strong Financials and Product Expansion PotentialAugust 15, 2024 | msn.comMediWound Q2 2024 Earnings PreviewSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mediwound Amid Market Expansion and Positive Growth ProspectsAugust 15, 2024 | seekingalpha.comMediWound Ltd. (MDWD) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | finanznachrichten.deMediWound Ltd.: MediWound Reports Second Quarter 2024 Financial Results and Provides Company UpdateAugust 14, 2024 | globenewswire.comMediWound Reports Second Quarter 2024 Financial Results and Provides Company UpdateAugust 12, 2024 | msn.comAST SpaceMobile (ASTS) to Post Q2 Earnings: What's in the Cards?August 5, 2024 | finanznachrichten.deMediWound Ltd.: MediWound Announces Positive Results from the U.S. NexoBrid Expanded Access Protocol (NEXT)August 5, 2024 | globenewswire.comMediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)August 2, 2024 | globenewswire.comMediWound to Report Second Quarter 2024 Financial ResultsJuly 29, 2024 | globenewswire.comMediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg UlcersSee More Headlines Receive MDWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MDWD CUSIPN/A CIK1593984 Webwww.mediwound.com Phone972779714100Fax972-77-971-4111Employees80Year Founded2001Price Target and Rating Average Stock Price Target$29.00 High Stock Price Target$30.00 Low Stock Price Target$28.00 Potential Upside/Downside+74.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,720,000.00 Net Margins-99.17% Pretax Margin-98.22% Return on Equity-52.49% Return on Assets-21.92% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.51 Sales & Book Value Annual Sales$20.14 million Price / Sales7.65 Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book8.65Miscellaneous Outstanding Shares9,284,000Free Float8,430,000Market Cap$154.11 million OptionableOptionable Beta0.83 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Ofer Gonen B.Sc. (Age 51)Chief Executive Officer Comp: $649kMs. Hani Luxenburg (Age 51)Chief Financial Officer Comp: $235kMr. Yaron Meyer Adv. (Age 45)Executive VP, General Counsel & Corporate Secretary Comp: $299kDr. Ety Klinger MBA (Age 62)Ph.D., Chief Research & Development Officer Comp: $377kDr. Lior Rosenberg M.D. (Age 78)Co-Founder Comp: $727kDr. Shmulik Hess Ph.D. (Age 51)COO & Chief Commercial Officer Mr. Barry J. Wolfenson (Age 57)Executive Vice President of Strategy & Corporate Development Dr. Robert J. Snyder CWS (Age 74)D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer More ExecutivesKey CompetitorsMenlo TherapeuticsNASDAQ:FOMXChromaDexNASDAQ:CDXCNatural Alternatives InternationalNASDAQ:NAIIMannatechNASDAQ:MTEXSNDLNASDAQ:SNDLView All CompetitorsInstitutional OwnershipSargent Investment Group LLCSold 5,857 shares on 8/10/2024Ownership: 1.277%Renaissance Technologies LLCSold 21,900 shares on 8/9/2024Ownership: 0.548%Rhumbline AdvisersBought 8,440 shares on 8/1/2024Ownership: 0.091%Bank of New York Mellon CorpBought 22,010 shares on 7/26/2024Ownership: 0.237%Rosalind Advisors Inc.Bought 27,500 shares on 7/12/2024Ownership: 5.533%View All Institutional Transactions MDWD Stock Analysis - Frequently Asked Questions How have MDWD shares performed this year? MediWound's stock was trading at $10.17 on January 1st, 2024. Since then, MDWD shares have increased by 63.2% and is now trading at $16.60. View the best growth stocks for 2024 here. How were MediWound's earnings last quarter? MediWound Ltd. (NASDAQ:MDWD) posted its quarterly earnings results on Wednesday, August, 14th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.26. The biopharmaceutical company earned $5.06 million during the quarter, compared to analysts' expectations of $5.07 million. MediWound had a negative net margin of 99.17% and a negative trailing twelve-month return on equity of 52.49%. When did MediWound's stock split? MediWound shares reverse split on the morning of Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. Who are MediWound's major shareholders? MediWound's top institutional investors include Rosalind Advisors Inc. (5.53%), Sargent Investment Group LLC (1.28%), Renaissance Technologies LLC (0.55%) and Bank of New York Mellon Corp (0.24%). How do I buy shares of MediWound? Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of MediWound own? Based on aggregate information from My MarketBeat watchlists, some other companies that MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA) and Mastercard (MA). This page (NASDAQ:MDWD) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediWound With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.